2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 434

IL-22 Mediated Pannus Formation in Autoimmune Arthritis Is PI3K/Akt/mTOR Dependent
Abstract Number: 2677

IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice
Abstract Number: 21

IL-32 and IL-17 Interact and Aggravate Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 897

IL-33 Promotes Mast Cell Survivial Via Inhibition of Apoptosis Associated with Enhanced Expression of Bcl-X_L
Abstract Number: 1743

IL-5-Induced FasL⁺ Regulatory B Cells Are Inhibited by IL-4 and Cyclosporine
Abstract Number: 1178

IL-6 and IL-21 in Rheumatoid Arthritis
Abstract Number: 2077

IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Abstract Number: 1762

IL-6 Receptor Inhibition by Tocilizumab Modulates Double Negative (CD19+IgD-CD27-) B Cells in RA
Abstract Number: 1281

IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
Abstract Number: 510

IL-7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7-Induced B Cell Activation in Primary Sjögren’s Syndrome
Abstract Number: 509

IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
Abstract Number: 328

IL-7; An Important Pro-Inflammatory Factor That Affects Myeloid Cell Function in RA and CIA
Abstract Number: 291

Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 868

Illness Perceptions Among Patients with Different Forms of Vasculitis
Abstract Number: 1022

Imaging of Ankle Joints by MRI in Murine Models of Inflammatory Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].